KEI hosted a virtual roundtable to discuss pathways to scale production, increase competition and speed the delivery of COVID-19 vaccines. Experts and policymakers exchanged views on the challenges and opportunities to scale production of COVID-19 vaccines. In this dialogue, experts addressed practical issues for the transfer of know-how and technology for manufacturing.
Questions and topics that were raised include:
1. Which vaccines represent the most significant opportunities in terms of scaling manufacturing capacity and enhancing access?
06:47 – Ingrid Kromann (CEPI)
10:45 – Alain Alsahani (MSF)
16:12 – Amine Kamen (McGill University)
19:23 – Fabrizio Chiodo (Italian National Research Council)
25:32 – James Krellenstein (Prep4All)
2. What incentives, mandates and/or subsidies are useful in expanding access to vaccine manufacturing know-how and capacity?
31:11 – James Love (KEI)
39:03 – Mariângela Simão (WHO)
48:26 – Kevin McCarthy (European Commission)
3. What is currently known about global manufacturing capacity for each relevant COVID-19 vaccine, and what measures are necessary to bring a facility into good manufacturing practice compliance for production of specific vaccines and other COVID-19 health technologies?
58:23 – Edward Hammond (independent consultant)
1:04:13 – Kris Howard (NRL Enterprise Solutions)
1:11:23 – Martin Friede (WHO)
1:15:50 – Fred Abbott (Florida State University)
1:20:48 – Tertia Bailey (Manufacturing Africa Adviser for Senegal and Cote d’Ivoire)
1:25:02 – KM Gopakumar (Third World Network)
4. What is the WHO prequalification program doing regarding COVID-19 vaccines?
5. What is the WHO C-TAP doing to expand manufacturing for COVID-19 vaccines?
1:29:48 – Erika Dueñas Loayza (WHO)
6. What is the Medicines Patent Pool doing to expand manufacturing for COVID-19 vaccines?
1:35:48 – Charles Gore (MPP)
7. What are national governments doing to scale and expand vaccine manufacturing access?
01:51:07 – Arianna Schouten (KEI)
8. What mistakes were made in 2020, and what mistakes need to be avoided in 2021?
01:54:13 – Peter Singer (WHO)
01:58:42 – Mohga Kamal-Yanni (senior advisor to the People’s Vaccine Alliance)
02:03:00 – Ellen ‘t Hoen (ML&P)
02:07:22 – Manuel Martin (MSF)
02:11:28 – Brook Baker (Health GAP)
Additional resources: https://www.keionline.org/covid-19-vaccine-manufacturing-capacity
KEI is also hosting an email list to share information, resources and news on these issues. To join the public, archived list, please visit: http://lists.keionline.org/mailman/listinfo/vaccine-manufacturing_lists.keionline.org
